Inozyme Pharma (INZY) Expected to Announce Quarterly Earnings on Tuesday

Inozyme Pharma (NASDAQ:INZY - Get Free Report) is anticipated to announce its earnings results before the market opens on Tuesday, March 11th. Analysts expect the company to announce earnings of ($0.42) per share for the quarter.

Inozyme Pharma Stock Performance

NASDAQ:INZY traded down $0.08 during mid-day trading on Friday, hitting $1.15. 414,739 shares of the company's stock traded hands, compared to its average volume of 508,070. The firm has a market capitalization of $73.88 million, a price-to-earnings ratio of -0.74 and a beta of 1.32. The firm has a 50 day moving average of $1.66 and a two-hundred day moving average of $3.40. The company has a current ratio of 7.68, a quick ratio of 7.68 and a debt-to-equity ratio of 0.51. Inozyme Pharma has a 12 month low of $1.04 and a 12 month high of $7.80.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on INZY shares. Raymond James initiated coverage on shares of Inozyme Pharma in a research report on Thursday, December 12th. They set an "outperform" rating and a $26.00 target price on the stock. HC Wainwright boosted their price target on Inozyme Pharma from $14.00 to $16.00 and gave the company a "buy" rating in a research note on Friday, January 10th. Piper Sandler cut their price objective on Inozyme Pharma from $43.00 to $30.00 and set an "overweight" rating for the company in a report on Monday, January 13th. Wedbush restated an "outperform" rating and issued a $12.00 target price on shares of Inozyme Pharma in a research note on Friday, January 10th. Finally, Wells Fargo & Company reduced their target price on shares of Inozyme Pharma from $14.00 to $11.00 and set an "overweight" rating on the stock in a research report on Monday, January 13th. Nine analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $18.33.

Remove Ads

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.